Skip to main content
OpenTrials
Completed

NCT Number: NCT07752771

Durability of Pulmonary Vein Isolation With Farapulse System Using Minimal Fluoroscopy

Objective: To evaluate the feasibility, acute, and three-month efficacy and safety of near-zero fluoroscopy PVI performed with the Farapulse system (Faravawe catheter, Faradrive sheath, Faraview module).

Primary hypothesis: High durability of PVI is achievable with minimal fluoroscopy PVI, using ICE-guided transseptal puncture and Farapulse system.

Study Design: Single-center, prospective, single-arm study. Investigator-initiated study.

Research period, expected enrollment rate: The planned research period starts in the third quarter of 2024. The expected enrollment rate is 4 patients/week. The enrollment and performance of the index procedure are expected to be completed within 1.5 - 2 months, and then three more months are required before the remap procedure.

Procedure: Standard PVI using Farapulse system and Faraview module. Follow-up: Invasive left atrial remap 3 months after the procedure. Imaging: CT and MRi scans to detect pulsed-field ablation scars before the FU procedure.

Endpoints:

* Primary endpoint: PVI durability at three months, detected by invasive left atrial remap, on a per PV basis. * Secondary endpoints:

* Continuity and size of the scar caused by the index ablation, detected on the cardiac MRI and CT before the remap (to compare it with the remapping data) * Door-to-door time (total time spent in the EP lab) * Skin-to-skin procedure time: time from the first femoral vein puncture to the removal of all sheaths * Left atrial dwelling time: time from inserting the long sheath in the left atrium to the sheath removal from the left atrium * Ablation time: time from the first until the last ablation * Fluoroscopy time and dose * Occurrence of any adverse events related to the procedure during the hospital stay at the 3 months remap the procedure

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Semmelweis University

Budapest, Pest County, 1122, Hungary

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Symptomatic paroxysmal AF
  • Age >18 years
  • Willingness to sign the informed consent form

Exclusion criteria

  • Contraindication to ablation
  • Contraindication of long-term anticoagulation
  • Persistent AF
  • History of typical or atypical flutter
  • History of PVI
  • History of cardiac surgery
  • Contraindication of cardiac MRi examination
  • Pregnancy
  • Active malignancy
  • Life expectancy <1 year
  • Valvular AF
  • Reversible cause of AF (e.g. hyperthyroidism).

Treatment and study plan

Catheter ablation

Device

Pulmonary vein isolation using Farapulse system with Faraview mapping

Primary outcomes

  1. PVI durability at three months

    Time frame: 3 months

    At three months, we perform an invasive left atrial remap. The primary outcome will be pulmonary vein reconnection. The outcome measure will be the risk (incidence) of pulmonary vein reconnection. The number of reconnected pulmonary veins will be collected.

Sponsors and collaborators

Lead sponsor

Semmelweis University

Other

Registry information

Acronym: Faraview Remap

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Aug 7, 2026
Registry last updated
Aug 7, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.